Zobrazeno 81 - 90
of 329
pro vyhledávání: '"Malcolm J. Moore"'
Autor:
Malcolm J. Moore, Stephen Welch
Publikováno v:
Future Oncology. 3:247-254
Epidermal growth factor receptor (EGFR) is overexpressed by several solid tumors, including pancreatic cancer, and has become an important target for novel anticancer pharmacotherapy. Erlotinib (Tarceva®, OSI-774) is an orally available small-molecu
Autor:
David Warr, Janet Dancey, David W. Hedley, Theodore A. Vandenberg, Mark Clemons, Susan Dent, Natasha B. Leighl, Malcolm J. Moore, Gregory R. Pond, Richard Tozer, R. Michael Crump
Publikováno v:
Breast Cancer Research and Treatment. 108:87-92
First- and second-line chemotherapy with anthracyclines and taxanes in metastatic breast cancer yield a modest improvement in survival with potentially significant toxicity. Subsequent lines of chemotherapy yield response rates of 20–25%, with an u
Autor:
Neesha Dhani, Mohammad R. Akbari, Steven A. Narod, Kara Semotiuk, Steven Gallinger, David W. Hedley, Spring Holter, Malcolm J. Moore, Robert C. Grant, Anna Dodd, Ayelet Borgida
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(28)
Purpose The main purpose of this study was to determine the prevalence of pathogenic BRCA1 and BRCA2 mutations in a consecutively ascertained clinic-based cohort of patients with pancreatic ductal adenocarcinoma and describe the clinical and family h
Autor:
Gregory R. Pond, Daniel Heng, Nevin Murray, Srikala S. Sridhar, Mary J. MacKenzie, Som D. Mukherjee, Robert Halford, Hui K Gan, S. Percy Ivy, Suzanne Richter, Christian Kollmannsberger, Masoom A. Haider, Malcolm J. Moore, Sebastien J. Hotte, Jo-An Seah
Publikováno v:
Canadian Urological Association journal = Journal de l'Association des urologues du Canada. 8(11-12)
Introduction: Pivotal phase III trials have positioned angiogenesis inhibitors as first-line therapy for the management of most advanced or metastatic renal cell carcinomas (mRCC). Approaches to second-line therapy, however, remain more controversial
Autor:
Ian F. Tannock, Jennifer J. Knox, Gina Lockwood, Monika K. Krzyzanowska, Georg A. Bjarnason, Malcolm J. Moore
Publikováno v:
Cancer Chemotherapy and Pharmacology. 60:135-141
The lack of effective systemic therapies for patients with advanced renal cell carcinoma (RCC) has stimulated interest in evaluating novel treatment strategies for this disease.This was a two-institution, two-stage, phase II trial of continuous low-d
Autor:
Malcolm J. Moore, Dominik Berthold
Publikováno v:
Expert Opinion on Therapeutic Targets. 10:777-780
Despite recent advances in the understanding of the cellular and molecular biology of prostate cancer, new options for the treatment of prostate cancer remain elusive. Targeted therapies have shown promising activities in many solid tumours and the g
Autor:
Paula N. Fishman, Gregory R. Pond, Malcolm J. Moore, Amit Oza, Ronald L. Burkes, Lillian L. Siu, Ronald Feld, Steven Gallinger, Paul Greig, Jennifer J. Knox
Publikováno v:
American Journal of Clinical Oncology. 29:225-231
Granuloma annulare is a dermatologic condition of unknown etiology. It most frequently presents on the extremities and trunk as skin-colored nodules arranged in an annular pattern. The lesions are usually asymptomatic and resolve spontaneously. Granu
Autor:
Pamela Degendorfer, Hal W. Hirte, Amit M. Oza, Gregory R. Pond, Malcolm J. Moore, Glenwood D. Goss, Lillian L. Siu, Carol A. Townsley, Eric Winquist
Publikováno v:
Clinical Cancer Research. 12:2141-2149
Background: The tolerability of molecularly targeted agents in older patients has not been specifically examined. Adverse event data from clinical trials in the Princess Margaret Hospital Phase II Consortium database were analyzed to address this que
Autor:
Patricia A. Tang, Malcolm J. Moore
Publikováno v:
American Journal of Cancer. 5:213-221
Pancreatic cancer is the fourth leading cause of cancer-related death in North America and is associated with an extremely bleak prognosis. Advances in the treatment of this devastating disease will require novel approaches. A key therapeutic strateg
Autor:
Timothy J. Hobday, Charles Erlichman, Hedy L. Kindler, Manisha H. Shah, Helen X. Chen, Jonathan R. Strosberg, Heinz-Josef Lenz, Malcolm J. Moore, Rui Qin, Diane Reidy-Lagunes, Andreas Kaubisch
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(14)
Purpose There are few effective therapies for pancreatic neuroendocrine tumors (PNETs). Recent placebo-controlled phase III trials of the mammalian target of rapamycin (mTOR) inhibitor everolimus and the vascular endothelial growth factor (VEGF)/plat